SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
World game at war: why some European nations have threatened a World Cup boycott 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
LAS VEGAS, May 08, 2018 -- CV Sciences, Inc., (OTCQB:CVSI) a preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a conference call to discuss its first quarter 2018 financial results on Tuesday, May 15, 2018 at 1:15pm PT / 4:15pm ET.
CV Sciences’ CFO Joseph Dowling will lead the call to provide an operational and financial summary of the first quarter ended March 31, 2018. Interested parties may access the live webcast by visiting: https://78449.themediaframe.com/dataconf/productusers/cvsciences/mediaframe/24633/indexl.html
In order to ensure adequate time for any software downloads that may be necessary to listen to the webcast, attendees are encouraged to connect to the website 10-15 minutes prior to the live event.
Participants may also access the listen-only audio call by dialing 1-877-407-8293 (United States) or 1-201-689-8349 (International). If you are unable to participate in the call at this time, a replay will be available for 14 days starting on May 15, 2018, at approximately 7:30 p.m. PT/10:30 p.m. ET. To access the replay, please dial 1-877-660-6853 in the U.S. and 1-201-612-7415 for international callers. The conference ID# is 13679917.
About CV Sciences, Inc.
CV Sciences, Inc (OTCQB:CVSI), located in Las Vegas, Nevada, focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the sale of CBD, and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. Additional information is available from OTCMarkets.com or by visiting PlusCBDoil.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
[email protected]
866-976-4784
